Related Experiment Video

Updated: May 6, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

11.3K

3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral

Rebecca L Hartman1,2, Nathalie A Desrosiers1,2, Allan J Barnes1

  • 1Chemistry and Drug Metabolism Section, Clinical Pharmacology and Therapeutic Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard, Suite 200 Room 05A721, Baltimore, MD, 21224, USA.

Analytical and Bioanalytical Chemistry
|November 16, 2013
PubMed

Insights

This study reveals significant differences in 3,4-Methylenedioxymethamphetamine (MDMA) and its metabolite levels between blood and plasma. Findings highlight sex- and race-based variations in MDMA metabolism, crucial for forensic toxicology.

Area of Science:

  • Forensic Toxicology
  • Pharmacokinetics
  • Analytical Chemistry

Background:

  • 3,4-Methylenedioxymethamphetamine (MDMA) is frequently used recreationally, with forensic analysis often relying on blood samples.
  • Previous research on MDMA pharmacokinetics primarily utilized plasma data, lacking direct comparisons with blood concentrations.
  • Understanding MDMA distribution in blood versus plasma is critical for accurate forensic interpretation.

Purpose of the Study:

  • To directly compare the pharmacokinetics of MDMA and its metabolites in human blood and plasma.
  • To investigate potential differences in MDMA metabolism based on sex and race.
  • To provide data for improved forensic interpretation of MDMA evidence.

Main Methods:

  • Quantification of MDMA, HMMA, MDA, and HMA in blood and plasma specimens from 50 volunteers using 2D GC-MS.
  • Volunteers received controlled doses of 1.0 and 1.6 mg/kg MDMA.
  • Analysis included C max, t first, t max, AUC0-3 h, and blood/plasma ratios up to 3 hours post-ingestion.

Main Results:

  • Median blood concentrations of MDMA and MDA were significantly higher than in plasma, while HMMA was lower.
  • Metabolite ratios (MDA/MDMA, MDA/HMMA) increased over time in blood, and HMMA/MDMA decreased.
  • Significant sex-based differences were observed in MDMA C max (females higher at low dose) and HMMA AUC0-3 h (females lower), and race-based differences in HMMA AUC0-3 h (African-Americans lower in plasma).

Conclusions:

  • Blood and plasma exhibit distinct pharmacokinetic profiles for MDMA and its metabolites.
  • Metabolic pathways for MDMA show significant variation between sexes and racial groups.
  • These findings are essential for accurate forensic analysis and understanding differential risk profiles associated with MDMA use.
Keywords:
BloodEcstasyMDMAMetabolitesPharmacokineticsPlasma

More Related Videos

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

26.5K
Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

13.6K

Related Concept Videos

Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
177
Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time01:02

Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time

When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
500
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
1.0K
First Pass Effect01:12

First Pass Effect

Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
10.5K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
921
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
126